Wei Hao, MD, PhD
Dr. Hao received his medical degree from Beijing Medical University (86’) and graduate degree in Endocrinology in Peking Union Medical College, Chinese Academy of Medical Sciences (89’). He then pursued his endocrinology research fellowship trainings at University of Florida and University of Washington, focusing on the autoimmune mechanism of type 1 diabetes and the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) in 90s.
After completed his clinical endocrinology fellowship at NIH Clinical Center in early 2000, he has been focusing on improvement of diabetes management with his most recent role as the Director of the Inpatient Diabetes Care Program at University of Washington Medical Center (UWMC). In this role, he was responsible for overseeing of a hospital-wide diabetes management team, education of clinicians involved in the care of patients with diabetes, and development of systems to improve glycemic management within UWMC. He was a Clinical Associate Professor of Medicine at Department of Medicine, University of Washington School of Medicine.
Dr. Hao recently joined the Benaroya Research Institute (BRI) at Virginia Mason in Seattle, WA. He is a Research Associate Member in Diabetes Clinical Research Program focusing on prevention and intervention for type 1 diabetes.
Area of Research
As a clinical investigator, Dr. Hao is actively participating in the Type 1 Diabetes TrialNet, an NIH sponsored international consortium to conduct multiple clinical trials in type 1 diabetes, and the clinical trials for type 1 diabetes with the NIH sponsored Immune Tolerance Network (ITN) as well as clinical research in T1D Exchange Clinic Network, a national consortium sponsored by the Helmsley Trust.
Dr. Hao is a board certified endocrinologist, in addition to his role at BRI, he also provides diabetes and endocrine care at Evergreen Health Medical Center. He has a special interest in intensive management of type 1 diabetes with insulin pump and sensor (continuous glucose monitor).
Hao W, Wookwyk A, Beam C, Greenbaum CJ. AIRMax is a Sensitive Measure of Bate Cell Function in at-Risk Individuals for Type 1 Diabetes. Manuscript submitted to Diabetologia for publication.
Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum1 CJ, Type 1 Diabetes TrialNet Study Group. Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care. 2016 Oct;39(10):1664-70. doi: 10.2337/dc16-0360. PMID: 27422577
Hao W, Greenbaum CJ, Krischer J, Cuthbertson D, Palmer JP. The Effect of the DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Post-prandial Glucose Tolerance. Diabetes Care. 2015 May;38(5):891-6. doi: 10.2337/dc14-1825. PMID: 25720600
Nair B, Grunzweig K, Peterson G, Horibe M, Neradilek M, Newman S, Van Norman G, Schwid HA, Hao W, Hirsch I, Dellinger P. Intraoperative Blood Glucose Management: Impact of a Real-Time Decision Support System on Adherence to Institutional Protocol. J Clin Monit Comput. 2016 Jun;30(3):301-12. doi: 10.1007/s10877-015-9718-3. PMID: 26067402
Grunzweig K, Nair B, Peterson G, Horibe M, Neradilek M, Newman S, Schwid HA, Van Norman G, Hao W, Dellinger P, Hirsch I. Decisional Practices and Patterns of Intra-operative Glucose Management in an Academic Medical Center. J Clin Anesth. 2016 Aug;32:214-23. doi: 10.1016/j.jclinane.2016.02.027. PMID: 27290979
Hao W, Skarulis MC, Simonds WF, Weinstein LS, Agarwal SK, Mateo C, James-Newton L, Gibril F, Jensen RT, Marx JS. Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab. 2004 Aug;89(8):3776-84. PMID: 15292304
Hao W, Davis C, Daniels T, Hampe C, Lernmark A. Epitope-specific glutamic acid decarboxylase-65 autoantibodies in intravenous immunoglobulin preparations. Transfus Med. 1999 Dec;9(4):307-10. PMID: 10583884
Hao W, Daniels T, Pipeleers , Smismans A, Reijonen H, Nepom GT, Lernmark A. Radioimmunoassay for glutamic acid decarboxylase-65. Diabetes Technol Ther. 1999 Spring;1(1):13-20. PMID: 11475299
Hao W, Davis C, Hirsch IB, Eng LJ, Daniels T, Walsh D, Lernmark A. Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year study. J Neurol. 1999 Aug;246(8):731-5. PMID: 10460456
Hao W, Myhre AP, Palmer JP. Nitric oxide mediates IL-1beta stimulation of heat shock protein but not IL-1beta inhibition of glutamic acid decarboxylase. Autoimmunity. 1999;29(2):93-101. PMID: 10433070
Hao W, Palmer JP. Islet cell function in type 1 and type 2 diabetes. J Clinical Ligand Assay. 1998:21:309-317.
Hao W, Gladstone P, Engardt S, Greenbaum C, Palmer JP. Major histocompatibility complex class I molecule expression is normal on peripheral blood lymphocytes from patients with insulin-dependent diabetes mellitus. J Clin Invest. 1996 Oct 1;98(7):1613-8. PMID: 8833910
Hao W, Palmer JP. The effects of cytokines on expression of glutamic acid decarboxylase-65 in cultured islets. Autoimmunity. 1995;22(4):209-18. PMID: 8781713
Hao W, Palmer JP. Recombinant human transforming growth factor beta does not inhibit the effects of interleukin-1 beta on pancreatic islet cells. J Interferon Cytokine Res. 1995 Dec;15(12):1075-81. PMID: 8746789
Hao W, Li L, Mehta V, Lernmark A, Palmer JP. The functional state of the beta cell affects expression of both forms of glutamic acid decarboxylase. Pancreas. 1994 Sep;9(5):558-62. PMID: 7809009
Mehta VK, Hao W, Brooks-Worrell BM, Palmer JP. Low dose interleukin-1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression. Eur J Endocrinol. 1994 Feb;130(2):208-14. PMID: 8130898
Hao W, Serreze DV, McCulloch DK, Neifing JL, Palmer JP. Insulin (auto)antibodies from human IDDM cross-react with retroviral antigen p73. J Autoimmun. 1993 Dec;6(6):787-98. PMID: 8155257
Mehta V, Hao W, Brooks-Worrell BM, Palmer JP. The functional state of the beta cell modulates IL 1 and TNF induced cytotoxicity. Lymphokine Cytokine Res. 1993 Aug;12(4):255-9. PMID: 8218598